Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

25-08-2022 | Neuroendocrine Tumor | ASO Author Reflections

ASO Author Reflections: Prognostic Factors in Gastrointestinal Extrapulmonary Small Cell Carcinoma Using Real-World Data

Authors: Mark B. Ulanja, MD, MPH, Bryce D. Beutler, MD, Daniel Antwi-Amoabeng, MD, MSc, Samuel B. Governor, MD, MPH, Ganiyu A. Rahman, MBBS, FWACS, Francis Tanam Djankpa, BSc, MPhil, PhD, Olatunji B. Alese, MD, FWACS

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

Gastrointestinal extrapulmonary small cell carcinoma (GI EPSCCa) is a rare subtype of high-grade neuroendocrine cancer with increasing incidence in the US.1 There is a paucity of data regarding the pattern of distribution, role of molecular aberrations, prognosis, and appropriate modalities of treatment in the management of this highly aggressive clinical entity. Limited available retrospective population-based studies are inconsistent on the role of surgical resection, chemotherapy, and radiation therapy (RT), including corresponding survival benefits. Guidelines for therapy are largely rudimentary.2,3 Given its rarity, randomized trials are very limited and retrospective studies continue to inform therapy. …
Literature
1.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol. 2017;3(10):1335–42.CrossRefPubMedPubMedCentral
2.
Mandish SF, Gaskins JT, Yusuf MB, Little BP, Dunlap NE. Extrapulmonary small cell carcinoma: prognostic factors, patterns of care, and overall survival. Eur J Surg Oncol. 2020;46(9):1596–604.CrossRefPubMed
3.
Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015;58(3):294–303.CrossRefPubMed
4.
5.
Metadata
Title
ASO Author Reflections: Prognostic Factors in Gastrointestinal Extrapulmonary Small Cell Carcinoma Using Real-World Data
Authors
Mark B. Ulanja, MD, MPH
Bryce D. Beutler, MD
Daniel Antwi-Amoabeng, MD, MSc
Samuel B. Governor, MD, MPH
Ganiyu A. Rahman, MBBS, FWACS
Francis Tanam Djankpa, BSc, MPhil, PhD
Olatunji B. Alese, MD, FWACS
Publication date
25-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12441-z

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

Hepatobiliary Tumors

Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population

ASO Author Reflections

ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?

ASO Author Reflections

ASO Author Reflections: Investigating the Relationship Between Patient Primary Language and Surgical Oncology Outcomes

Thoracic Oncology

Prognostic Impact from the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer

ASO Author Reflections

ASO Author Reflections: The Clinical Use of Radiomics with Artificial Intelligence in Patients with Early-Stage Lung Cancer

ASO Visual Abstract

ASO Visual Abstract: Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer